CJC-1295 (no DAC)
100 mcg · Daily or EOD
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 6
- Animal Studies
- 15
- Clinical Status
- Off-label
- Confidence
- Low
- Long-Term Safety
- Limited — most human GHRH-analogue safety data comes from related approved drugs (e.g. tesamorelin), not this specific compound
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A growth hormone-releasing hormone (GHRH) analogue without the DAC extension that longer-acting versions use, giving it a short half-life (~30 min) and a pulsatile GH-release pattern closer to natural physiology. Often stacked with a GHRP like Ipamorelin.
Common Protocols
- 100 mcg daily or every other day, subcutaneous, often paired with Ipamorelin
- Short half-life means timing (e.g. before bed, fasted) matters more than with DAC-modified versions
Side Effects
- Injection site reaction
- Flushing or mild headache reported anecdotally
- Water retention possible from GH elevation
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 2 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Teichman SL et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. PMID 16352683.
- Dominikowski A et al. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol. PMID 42395176.
- Mayfield CK et al. (2026). Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. PMID 41476424.
Search the Research
CJC-1295 (no DAC) FAQ
What is the typical CJC-1295 (no DAC) dosage?
Commonly reported protocols: 100 mcg daily or every other day, subcutaneous, often paired with Ipamorelin; Short half-life means timing (e.g. before bed, fasted) matters more than with DAC-modified versions. Our reference entry uses 100 mcg, Daily or EOD. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of CJC-1295 (no DAC)?
Reported side effects include: Injection site reaction; Flushing or mild headache reported anecdotally; Water retention possible from GH elevation.
Is CJC-1295 (no DAC) FDA approved?
CJC-1295 (no DAC) is not FDA approved for the uses discussed here; it is used off-label or through compounding pharmacies, with less oversight of quality and dosing.
How much research is there on CJC-1295 (no DAC)?
Our evidence profile counts roughly 6 human and 15 animal studies, with low overall confidence. Long-term safety: Limited — most human GHRH-analogue safety data comes from related approved drugs (e.g. tesamorelin), not this specific compound.
Does CJC-1295 (no DAC) interact with other drugs or supplements?
Combining with other GH secretagogues compounds both effect and risk.
How do I reconstitute CJC-1295 (no DAC)?
A common setup is a 2 mg vial mixed with 2 mL of bacteriostatic water, which puts a 100 mcg dose at about 10 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Compare
Related compounds
GHRH analogue; stack with Ipamorelin